Table 6.
ER+ tumors vs. tumor-adjacent normal tissues | ER- tumors vs. tumor-adjacent normal tissues | |||||||
---|---|---|---|---|---|---|---|---|
Probeset ID | Entrez ID | Symbol | Log2(FC) | t valuea | FDRb | Log2(FC) | t valuea | FDRb |
TC0401141 | 125 | ADH1B | −1.33 | −21.1 | 2.92E-61 | −1.32 | −11.0 | 1.59E-14 |
TC0901044 | 216 | ALDH1A1 | −0.61 | −16.7 | 2.77E-44 | −0.58 | −8.6 | 6.93E-11 |
TC0401142 | 126 | ADH1C | −0.25 | −14.6 | 3.80E-36 | −0.29 | −7.6 | 3.08E-09 |
TC1100272 | 847 | CAT | −0.34 | −10.2 | 1.99E-20 | −0.32 | −4.2 | 6.20E-04 |
TC1200702 | 217 | ALDH2 | −0.18 | −7.0 | 6.53E-11 | −0.20 | −4.0 | 1.01E-03 |
TC0401137 | 128 | ADH5 | −0.11 | −4.8 | 7.69E-06 | −0.04 | −0.7 | 6.00E-01 |
TC1000709 | 1571 | CYP2E1 | −0.02 | −1.9 | 8.21E-02 | −0.02 | −0.6 | 7.02E-01 |
ER estrogen receptor, NHS Nurses’ Health Study, FDR false discovery rate, FC fold change
aThe t values were obtained from paired t tests of tumor and adjacent normal tissues: 357 pairs of ER+ tumor and ER+ tumor-adjacent normal tissues, and 86 pairs for ER- tumor and ER- tumor-adjacent normal, respectively
bFDR was calculated across all the 25,979 probes